The Role of Genetic Factors in the Development of Atopic Dermatitis in the Kazakh Population

Atopic Dermatitis Clinical Trial

Official title:

Preventive and Personalized Medicine (2021-2023)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05090631
• Other study ID #: 1196
• Status: Completed
• Start date: October 23, 2021
• Est. completion date: January 20, 2023

Study information

• Verified date: March 2023
• Source: Asfendiyarov Kazakh National Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a GWAS study that aims to identify possible candidate genes associate to atopic dermatitisby exploring single nucleotide polymorphism (SNP) in a group of atopic dermatitis, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with atopic dermatitis

Description:

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 600
• Est. completion date: January 20, 2023
• Est. primary completion date: January 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Persons with various forms of a confirmed diagnosis of atopic dermatitis;

• The age of the patients is from 18 to 45+ years;

• Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs.

• Persons who are able and willing to provide written informed consent;

• Persons capable and willing to comply with the research protocol;

Exclusion Criteria:

• Persons under the age of 18;

• Patients with severe concomitant systemic diseases, including cardiovascular, respiratory, hepatic and renal failure

• Patients with severe infectious processes (sepsis, abscess, hepatitis B and C, HIV)

• Persons with mental illness.

• Persons taking corticosteroid drugs, immunosuppressants within the last month;

• Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;

• Pregnant or lactating women;

• Tuberculosis of any localization in the active phase and in history;

• Severe and decompensated diseases of the liver and kidneys, cardiovascular system;

• Severe and decompensated course of endocrine diseases;

• Autoimmune diseases;

• Systemic diseases;

• Oncological diseases;

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Genetic:
• DNA analysis
GWAS

Locations

Country	Name	City	State
Kazakhstan	Kazakhstan	Almaty

Sponsors (1)

Lead Sponsor	Collaborator
Asfendiyarov Kazakh National Medical University

Country where clinical trial is conducted

Kazakhstan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of SNPs associated with atopic dermatitis	Using GWAS to identify candidate genes associate with atopic dermatitis	1 year